From a pharma executive to a top-secret CIA official, a top pharma exec who made $100,000 in a year and a top CIA official who made over $1 million in a single year, a pharmaceutical executive who got paid more than $200,000, a pharmas chief executive who made more than a billion dollars and a CIA official whose salary was more than six figures.
Read moreWhat to know about the biggest drug companies and how they make moneyThe big pharma CEOs are paid more by the pharmaceutical industry than the top 50 U.S. CEOs and the top 5 U.K. CEOs, according to an analysis by the Center for Responsive Politics.
They also receive more than half the government’s foreign aid, according for-profit universities, corporate headquarters and government contracts.
The drug companies themselves, by contrast, have earned billions of dollars in the past decade thanks to an expansion of the drugs market.
The pharmaceutical industry, which has been largely driven by a merger of drugmakers Pfizer and Allergan, has earned more than twice as much in the U.M.
Feds, which also includes drugmakers Bristol-Myers Squibb and Pfizer, together earned nearly $1.3 trillion last year.
The industry has a $17.5 trillion market value.
The industry is also making billions of annual profits, according a study by the nonpartisan Congressional Research Service, and is the third largest employer in the country.
It employs more than 10 million people and pays nearly $3 trillion in taxes.
But the CEOs of these companies are paid so little that the average CEO in the top five paid $3.5 million last year, the study found.
The top five top paid CEOs were all paid over $100 million, and were in the $500,000 to $1 billion range.
That includes the CEO of AstraZeneca, David J. Blatter, who made an estimated $200 million last quarter, according the AP.
The CEO of Turing Pharmaceuticals, Martin Shkreli, made $1,890,000 last year and earned $15 million.
The CEOs of Pfizer’s Merck, Bristol-myers Squab and Abbott Laboratories all made more money than Pfizer did last year thanks to the merger of the companies.
In total, the top 100 drugmakers earned $9.6 billion in profit last year in the United States.
They were worth $10.4 trillion in U.N. contracts, and their assets totaled $22.3 billion, according data from the Federal Reserve.
AstraZeneca and Bristol-MYERS Squibeb, both the world’s biggest drugsmakers, earned $3 billion each.
Abbott, the biggest maker of antibiotics, earned just $1 for each of its 4,000 employees.
Turing Pharmaceuticals made a $3 million profit, according AP.
Tequila, which was sold to Teva Pharmaceuticals for $6.7 billion in 2011, was the biggest winner.
Its shares, which were up 1.8% on Friday, have since fallen 20% since then.
Pfizer had a 6.3% gain last year as its drug profits increased.
In a statement, Teva said the merger “allowed Pfizer to expand its product portfolio in a highly competitive market while maintaining its core business.”
It also said the transaction has “created significant opportunities for new products and opportunities for growth and job creation for all stakeholders.”
The pharmaceuticals companies said they will invest $100 billion over the next five years to develop and develop new treatments for chronic diseases, and said they are developing innovative new treatments to treat a variety of cancers, including breast cancer.
Bristol-Myer, the largest drugmaker in the world, said it is investing $5 billion in research and development in a new form of cancer treatment called metastatic lung cancer.
The company also plans to invest $10 billion over three years to fight prostate cancer.
Its executives also have an opportunity to earn millions of dollars from other lucrative areas of the company.
It is investing heavily in the technology that powers drones and is developing a robot for the delivery of food.
The company also is working on a drug that will help people who have been infected with Ebola recover from the disease.
The drug could be a first in the industry for a virus that is not contagious and has not spread to other countries.
Read MoreTrump administration wants to ban most foreign aidThe United States and other countries are sending billions of federal dollars to the global drug industry.
The pharmaceutical companies pay far less than their foreign competitors, which makes the money much easier to transfer overseas.
The companies also receive an unfair amount of foreign aid from the United Nations.
Ns budget for international health is just under $50 billion a year, according Reuters, and it includes almost $6 billion for medical research.
The United States spends more than